Genmab - ADR
GMAB
Market Cap$15.69B
Close$
$9.43
65.7% downside
Current Fair Value
65.7% downsideOvervalued by 65.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $15.69 Billion |
|---|---|
| Enterprise Value | $14.59 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $12.14 |
| Beta | 0.8 |
| Outstanding Shares | 617,647,050 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 17.38 |
|---|---|
| PEG | -22.83 |
| Price to Sales | 1.25 |
| Price to Book Ratio | 3.44 |
| Enterprise Value to Revenue | 1.07 |
| Enterprise Value to EBIT | 3.13 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Genmab
CEO: Jan van de Winkel